Close this search box.

Overcoming Challenges in Cell and Gene Therapy: Navigating a Path Toward a Promising Future

There’s no denying that cell and gene therapies (CGTs) are shaping the future of medicine and healthcare as we know it. Expected to reach $14 billion by 2025, the CGT market is set to introduce approximately 10–20 new products every year in the United States alone. These therapies aren’t just transforming treatments; they’re granting patients a second chance at life.

Unlike other therapeutic approaches, cell and gene therapies have the potential to serve as a one-time treatment, offering benefits that span a patient’s lifetime. This is due to their ability to provide the body with “immunological memory,” meaning that a person’s immune system stores information about a certain stimulus, like a cancer cell, so it can be destroyed if encountered again.

Chimeric antigen receptor (CAR) T-cell therapy, in particular, has demonstrated remarkable success in treating certain cancer types, but it’s not without its challenges. From diverse toxicities that can be fatal, to its ineffectiveness against all cancer types and concerns surrounding limited persistence, poor tumor infiltration, and immunosuppressive microenvironments, the hurdles are numerous. Accessibility remains a major concern, with only 20% of eligible patients able to access the treatment, largely due to the high cost and lengthy manufacturing process. Until these limitations are addressed, the full potential of CAR T-cell therapy remains untapped.

The Difficult and Complex Journey of Bringing CGTs to Commercialization

One of the biggest obstacles that companies face when developing cell and gene therapies is optimizing their manufacturing. These therapies are customized to fit each patient’s unique needs, which makes the process complicated and time-consuming. With so much variability, maintaining control over cell quality is critical. Even the slightest manufacturing error could have severe consequences for patients, necessitating the use of in-process controls and analytical tools to monitor critical quality attributes (CQAs) and ensure strict quality standards are met.

Beyond manufacturing, the delivery of cell-based therapies involves overcoming significant barriers, including supply chain, travel, and logistics as well as vendor/partner collaboration to ensure the product gets to the patient. Companies rely on a robust supply chain equipped with advanced capabilities to ensure the therapy reaches the patient quickly and safely. Once a CGT is produced, it must be administered to the patient safely and effectively, typically through methods like injection or infusion. To achieve this, meticulous planning and coordination are required, involving travel and logistics.

Clinical trials for cell and gene therapies are not without their own unique set of challenges. The highly personalized nature of CGTs often makes it difficult to find a sufficient number of patients with the same condition for trial participation. Enrolling patients in gene therapy clinical trials, particularly for rare diseases, can be challenging. According to McKinsey, these rare conditions lead to “intense competition for a limited patient pool to treat,” impacting R&D timelines, especially during the clinical trial phase, and overall costs. Furthermore, given the potential for severe side effects with CGTs, rigorous monitoring of patients during clinical trials is essential.

Post-launch, these therapies continue to face hurdles. The same factors that complicate clinical trials— limited patient pools and the need for meticulous monitoring—also affect post-launch success. After receiving regulatory approval, therapies for rare diseases often struggle to reach all eligible patients due to the scattered patient population and challenges related to diagnosis and treatment access.

Furthermore, post-launch, the long-term safety and efficacy of these therapies continue to be under scrutiny. Rigorous post-marketing surveillance is required to monitor the long-term effects of the therapy and manage any unforeseen adverse events.

Close Collaboration Key for Success

Despite the challenges faced, the promise of cell and gene therapies is too significant to ignore. Overcoming these difficulties requires collaboration among many stakeholders. Each team plays a unique role in the process, and their effective collaboration is crucial for the success of CGT clinical trials:

  • Clinicians: Doctors and nurses are on the front lines, administering therapies and monitoring patients for side effects. They are also instrumental in gathering data about the therapy’s effectiveness and safety.
  • Manufacturers: The production of CGTs is a complex process, requiring specialized facilities and trained staff. Manufacturers are responsible for producing safe, high-quality therapies.
  • Market Access Teams: Once a CGT has been approved, market access teams work to ensure that it is accessible and affordable for patients. They may work with insurance companies, government agencies, and healthcare providers to negotiate pricing and reimbursement.
  • Patient Services and Advocates: These individuals play a crucial role in representing the interests of patients. They ensure that patients’ needs are met and that they are informed about the trial’s progress. They also advocate for patient access to these innovative therapies.

To overcome the challenges associated with bringing CGTs to commercialization, several solutions can be applied:

  • Optimizing the Manufacturing Process: Innovations in biotechnology are paving the way for more efficient production of CGTs. For instance, automation and closed-system manufacturing can help streamline the production process, reduce the risk of contamination, and maintain consistent quality. Novel analytical tools and technologies can also help monitor critical quality attributes (CQAs) more effectively.
  • Enhancing Supply Chain Management: Advanced logistics and supply chain management solutions are crucial for ensuring the timely and safe delivery of CGTs. Cold chain logistics, which involve maintaining a constant low temperature throughout the shipment process, can help preserve the quality of these therapies.
  • Improving Clinical Trials: The use of decentralized clinical trials, where patients can participate from their homes, can help increase patient recruitment, especially for rare diseases. Additionally, real-world evidence can be leveraged to complement clinical trial data and provide more insights about the therapy’s long-term effects.
  • Expanding Patient Access Post-Launch: Collaborative efforts between manufacturers, healthcare providers, and payers can help improve access to CGTs. This includes implementing patient support programs, educating healthcare providers about the new therapy, and negotiating with insurance companies for coverage.
  • Rigorous Post-Marketing Surveillance: Implementing robust drug safety systems can help closely monitor the safety and efficacy of CGTs after they have been launched. This includes tracking adverse events, collecting patient feedback, and conducting post-marketing studies

The Claritas Rx Difference

The patient treatment journey can be a complex and intricate process involving multiple stakeholders and potential barriers. At Claritas Rx, we understand the importance of removing these barriers through timely and effective communication with customers. Our trade and operations expertise enables us to offer customized services tailored to each patient’s unique needs. From ingestion to validation and integration of external data sources, our solution offers real-time data processing and advanced reporting capabilities, supporting rapid decision-making. By streamlining the therapy delivery process, we aim to make every minute count for patients and their healthcare providers.

Our flexible analytics provide continuous oversight, allowing us to identify at-risk patients faster and take action to ensure timely treatment. With our patient journey tracker, we’re able to offer real-time insight into where patients are in their treatment journey, while our AI model can predict when patients will experience issues with access to treatment.

Our goal is to simplify the complexities of CGT through a single source of truth, enabling real-time collaboration across teams and ensuring patients can access treatment when and where they need it.

As we strive to innovate and advance cell and gene therapies, we are shaping a brighter future for medicine. Armed with the right tools, and a collaborative partner like Claritas Rx, it’s possible to overcome any challenges that arise, ultimately achieving our end goal of enhancing patient lives and delivering better outcomes.

Images used under license by